Tenax Therapeutics (TENX) Interest Expenses (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Interest Expenses of $58.6 million for Q2 2026, up 2929750.0% year-over-year from N/an in Q2 2025, and down 16.18% on a QoQ basis from $69.9 million in Q1 2026.
Tenax Therapeutics (TENX) Interest Expenses (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Interest Expenses for 16 years, with the latest figure at $58.6 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $58.6 million, up 2929750.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $58.6 million (up 2929750.0% YoY), and the FY2025 annual result was $50.4 million, up 20.82% from the prior year.
- Interest Expenses retreated to $58.6 million in Q2 2026, from $69.9 million in the prior quarter.
- Over five years, Interest Expenses peaked at $69.9 million in Q1 2026 and troughed at -$1000.0 in Q4 2024.
- A 5-year average of $8.8 million and a median of $17103.0 in 2023 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2024, when Interest Expenses plunged 145.72%; it then soared 3662131.53% in 2026.
- A 5-year view of Interest Expenses shows it stood at $227546.0 in 2022, then tumbled by 99.04% to $2187.0 in 2023, then plunged by 145.72% to -$1000.0 in 2024, then jumped by 1100100.0% to $11.0 million in 2025, then soared by 432.7% to $58.6 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $58.6 million in Q2 2026, $69.9 million in Q1 2026, and $11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.60 Mn |
| Jun 30, 2026 | 58.60 Mn |
| Mar 31, 2026 | 69.91 Mn |
| Mar 31, 2026 | 69.91 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 1,909.00 |
| Mar 31, 2025 | 1,909.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 2,849.00 |
| Dec 31, 2023 | 2,849.00 |
| Sep 30, 2023 | 16,089.00 |
| Sep 30, 2023 | 16,089.00 |